Companies: 10,795·Total market cap: $144.5T
HLS Therapeutics Inc.

HLS Therapeutics Inc.

HLS.TOTSXHealthcare● Active
$4.40
$-0.07(-1.57%)
Market Cap$137604280
P/E Ratio—
52W High$5.765
52W Low$0.001
Shares OutstandingFinancialsRevenue

HLS Therapeutics Inc. (HLS.TO) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

HLS.TO · shares outstanding · updated Jun 8, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
31.5M▼ -0.98% YoY Change
FY · as of Dec 31, 2025 · Reported in USD
vs 31.8M in FY 2024
Diluted Shares Outstanding
31.5M
incl. options, RSUs, convertibles
Dilution Spread
+0.00%
Diluted vs Basic
YoY Change
-0.98%
year-over-year
Float (Free Float)
31.1M
publicly tradable shares
99.3% of total
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-08

Shares Outstanding Growth Rate

3-Year CAGRdeclining
-0.8%
2022 → 2025
5-Year CAGRdeclining
-0.1%
2020 → 2025
10-Year CAGRincreasing
+6.0%
2015 → 2025
ⓘ

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2025Latest
Diluted Shares: 31.5M
31.5M
-0.98%
FY 2024
Diluted Shares: 31.8M
31.8M
-1.31%
FY 2023
Diluted Shares: 32.3M
32.3M
-0.19%
FY 2022
Diluted Shares: 32.4M
32.3M
+0.44%
FY 2021
Diluted Shares: 32.2M
32.2M
+1.48%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs HLS.TO
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+>999%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+>999%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+>999%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+>999%
#5
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M+>999%
#6
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M+>999%
#7
HLS Therapeutics Inc.HLS.TO
HLS Therapeutics Inc.YOU
31.5M—

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

HLS Therapeutics Inc. (HLS.TO) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2025, HLS Therapeutics Inc. reports 31.5M basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

HLS Therapeutics Inc.'s basic shares outstanding (31.5M) represents currently issued shares. Diluted shares outstanding (31.5M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.00%.

Shares Outstanding vs. Float (Free Float)

HLS Therapeutics Inc.'s float is 31.1M (99.3% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float31.1M(99.3%)
Outstanding31.3M

ⓘ Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · USD

About shares outstanding & methodology

HLS Therapeutics Inc. (HLS.TO) shares outstanding history from 2006 to 2025. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

HLS Therapeutics Inc. shares outstanding for the fiscal year ending December 31, 2025 were 31.5M, a 0.98% decline year-over-year. HLS Therapeutics Inc. FY 2025 shares outstanding were 31.5M, a -0.98% decline from FY 2024.

HLS Therapeutics Inc. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of +6.0% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.
Market capSplitsEarningsFinancials (Income)Cash on handFree cash flowNet incomePrice history

Frequently asked questions

HLS.TO shares outstanding · 4 questions

As of December 31, 2025, HLS Therapeutics Inc. (HLS.TO) has approximately 31.5M basic shares outstanding and 31.5M diluted shares outstanding. This represents a -0.98% year-over-year change from FY 2024 (31.8M). HLS Therapeutics Inc.'s declining share count is primarily driven by its share buyback program. For the complete historical data table, see the history table above.

HLS.TO shares outstandinghow many shares does HLS.TO haveHLS.TO basic shares 2025HLS.TO diluted shares

▸ Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · HLS Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-08